tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Palvella Therapeutics price target lowered to $52 from $53 at Canaccord

Canaccord analyst Whitney Ijem lowered the firm’s price target on Palvella Therapeutics (PVLA) to $52 from $53 and keeps a Buy rating on the shares. The firm said its 1Q25 earnings report was incrementally positive relative to our recent initiation. Pipeline progress remains on track, and newly announced was that QTORIN rapamycin’s Ph3 had exceeded the target enrollment goal of n=40 ahead of schedule.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1